Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072356 · ClinicalTrials.gov registry record · Early Phase 1
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
A Early Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 290
- Enrollment target
NCT02072356: Completed Early Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT02072356 is a Early Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 290 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (447% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02072356, a Early Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 290 participants
- Enrollment target
Study Summary
This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be an effective treatment for liver cancer.
Interventions
- OTHER laboratory biomarker analysis
- RADIATION yttrium Y 90 glass microspheres
- DRUG TheraSphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2010-10-11 |
| Est. Completion | 2021-06-15 |
| Phase | Early Phase 1 |
What the finished NCT02072356 record still lists
NCT02072356 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (447% higher).
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02072356 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02072356 about?
NCT02072356 is a clinical study titled "Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery". This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kil...
What is the current status of trial NCT02072356?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 290 participants. The study started on 2010-10-11. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT02072356?
The interventions under investigation include: laboratory biomarker analysis (OTHER), yttrium Y 90 glass microspheres (RADIATION), TheraSphere (DRUG).
Who is sponsoring clinical trial NCT02072356?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02072356's enrollment target sits among peer trials
290 37th of 2000 higher than 1,963 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI